These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
94 related articles for article (PubMed ID: 8702313)
1. [Molecular analysis of the estrogen receptor (ER) gene in association with ER negativity in breast cancer]. Iwase H; Kobayashi S; Iwata H; Yamashita T; Ito K; Toyama T; Hara Y; Greenman J; Mathew CG Gan To Kagaku Ryoho; 1996 Mar; 23 Suppl 1():61-5. PubMed ID: 8702313 [TBL] [Abstract][Full Text] [Related]
2. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial. Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363 [TBL] [Abstract][Full Text] [Related]
3. Association of p53 genetic polymorphism (Arg72Pro) with estrogen receptor positive breast cancer risk in Japanese women. Noma C; Miyoshi Y; Taguchi T; Tamaki Y; Noguchi S Cancer Lett; 2004 Jul; 210(2):197-203. PubMed ID: 15183535 [TBL] [Abstract][Full Text] [Related]
4. Analysis of the PvuII restriction fragment-length polymorphism and exon structure of the estrogen receptor gene in breast cancer and peripheral blood. Yaich L; Dupont WD; Cavener DR; Parl FF Cancer Res; 1992 Jan; 52(1):77-83. PubMed ID: 1345763 [TBL] [Abstract][Full Text] [Related]
5. Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype. Rakha EA; El-Sayed ME; Green AR; Paish EC; Powe DG; Gee J; Nicholson RI; Lee AH; Robertson JF; Ellis IO J Clin Oncol; 2007 Oct; 25(30):4772-8. PubMed ID: 17876012 [TBL] [Abstract][Full Text] [Related]
6. BRCA1 and BRCA2 mutation status and tumor characteristics in male breast cancer: a population-based study in Italy. Ottini L; Masala G; D'Amico C; Mancini B; Saieva C; Aceto G; Gestri D; Vezzosi V; Falchetti M; De Marco M; Paglierani M; Cama A; Bianchi S; Mariani-Costantini R; Palli D Cancer Res; 2003 Jan; 63(2):342-7. PubMed ID: 12543786 [TBL] [Abstract][Full Text] [Related]
7. Progesterone receptor loss correlates with human epidermal growth factor receptor 2 overexpression in estrogen receptor-positive breast cancer. Kim HJ; Cui X; Hilsenbeck SG; Lee AV Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1013s-1018s. PubMed ID: 16467118 [TBL] [Abstract][Full Text] [Related]
8. Detection of loss of heterozygosity of p53 gene in paraffin-embedded breast cancers by non-isotopic PCR-SSCP. Chen YH; Li CD; Yap EP; McGee JO J Pathol; 1995 Oct; 177(2):129-34. PubMed ID: 7490678 [TBL] [Abstract][Full Text] [Related]
9. Expression of estrogen receptor (ER) (beta)cx protein in ER(alpha)-positive breast cancer: specific correlation with progesterone receptor. Saji S; Omoto Y; Shimizu C; Warner M; Hayashi Y; Horiguchi S; Watanabe T; Hayashi S; Gustafsson JA; Toi M Cancer Res; 2002 Sep; 62(17):4849-53. PubMed ID: 12208729 [TBL] [Abstract][Full Text] [Related]
10. TP53 and MYC gene alterations independently predict poor prognosis in breast cancer patients. Berns EM; Klijn JG; Smid M; van Staveren IL; Look MP; van Putten WL; Foekens JA Genes Chromosomes Cancer; 1996 Jul; 16(3):170-9. PubMed ID: 8814449 [TBL] [Abstract][Full Text] [Related]
11. Loss of heterozygosity at 17p13.3-ter, distal to TP53, correlates with negative hormonal phenotype in sporadic breast cancer. Roncuzzi L; Brognara I; Baiocchi D; Amadori D; Gasperi-Campani A Oncol Rep; 2005 Aug; 14(2):471-4. PubMed ID: 16012732 [TBL] [Abstract][Full Text] [Related]
12. CASP8 polymorphisms, estrogen and progesterone receptor status, and breast cancer risk. Han S; Lee KM; Choi JY; Park SK; Lee JY; Lee JE; Noh DY; Ahn SH; Han W; Kim DH; Hong YC; Ha E; Yoo KY; Kang D Breast Cancer Res Treat; 2008 Jul; 110(2):387-93. PubMed ID: 17940865 [TBL] [Abstract][Full Text] [Related]
13. Is triple negative a prognostic factor in breast cancer? Nishimura R; Arima N Breast Cancer; 2008; 15(4):303-8. PubMed ID: 18369692 [TBL] [Abstract][Full Text] [Related]
14. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast. Hussein MR; Abd-Elwahed SR; Abdulwahed AR Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077 [TBL] [Abstract][Full Text] [Related]
15. [The expression of c-myb is strongly associated with the presence of estrogen and progesterone receptors in breast cancer]. Guerin M; Barrois M; Riou G C R Acad Sci III; 1988; 307(20):855-61. PubMed ID: 2907731 [TBL] [Abstract][Full Text] [Related]
16. Sequence variants of the estrogen receptor (ER) gene found in breast cancer patients with ER negative and progesterone receptor positive tumors. Iwase H; Greenman JM; Barnes DM; Hodgson S; Bobrow L; Mathew CG Cancer Lett; 1996 Nov; 108(2):179-84. PubMed ID: 8973592 [TBL] [Abstract][Full Text] [Related]
17. Impact of metastatic estrogen receptor and progesterone receptor status on survival. Lower EE; Glass EL; Bradley DA; Blau R; Heffelfinger S Breast Cancer Res Treat; 2005 Mar; 90(1):65-70. PubMed ID: 15770528 [TBL] [Abstract][Full Text] [Related]
18. Estrogen receptor expression in human breast cancer associated with an estrogen receptor gene restriction fragment length polymorphism. Hill SM; Fuqua SA; Chamness GC; Greene GL; McGuire WL Cancer Res; 1989 Jan; 49(1):145-8. PubMed ID: 2562795 [TBL] [Abstract][Full Text] [Related]
19. Relationship of clone 4 estrogen receptor variant messenger RNA expression to some known prognostic variables in human breast cancer. Murphy LC; Hilsenbeck SG; Dotzlaw H; Fuqua SA Clin Cancer Res; 1995 Feb; 1(2):155-9. PubMed ID: 9815968 [TBL] [Abstract][Full Text] [Related]
20. Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy. Bartlett JM; Ellis IO; Dowsett M; Mallon EA; Cameron DA; Johnston S; Hall E; A'Hern R; Peckitt C; Bliss JM; Johnson L; Barrett-Lee P; Ellis P J Clin Oncol; 2007 Oct; 25(28):4423-30. PubMed ID: 17906205 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]